XNAS · VKTX
+5.21% · +$1.51 · Vol 5.1M
After hours · updated 18:45:25 ET
Viking Therapeutics, Inc

Viking Therapeutics, Inc

PHARMACEUTICAL PREPARATIONS
$30.50
Card
Relationship Map

Follow $VKTX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $VKTX by email

Veridion Score

BETALOW CONF · 6 of 6 factors measuredMethodology
VKTX
Viking Therapeutics, Inc
Mon Sep 21 · session closed · Markets closed · resumes Tue 9:30 ET
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

43/ 100
Veridion Score
Lower range · LOW confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6 of 6 factors measured · Mon Sep 21 · session closed · Markets closed · resumes Tue 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is VKTX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading VKTX catalysts
About Viking Therapeutics, Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2015
Employees
65
Country
US

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$29.57
Day high
$30.70
Day low
$28.41
Previous close
$28.99
52W high
$42.13
-27.61% from high
52W low
$24.97
32% of range
Market cap
$3.4B
EPS
$-2.9000
Beta
1.07
Shares out
116.7M
Volume
5.1M
2.53× rel vol
Avg volume
2M
VWAP
$29.53
Price history computed in-house
1W
-3.27%
1M
-10.00%
3M
-12.38%
1Y
+20.08%
YTD
-13.30%
SMA 50 $33.78 · below
SMA 200 $33.28 · below
52W position 32%

VKTX overview

Veridion Score
43
Registered · 2026-09-21
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around VKTX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading VKTX Form 4 filings
Public disclosures

Congress activity in VKTX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for VKTX in the cached public ledger.

Federal contracts

VKTX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for VKTX in this window.
Lobbying spend

VKTX lobbying filings, year to date.

Registered lobbying filings matched to Viking Therapeutics, Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for VKTX in this window.
Loading news for VKTX
Analyst ratings
Sovereign unlock shows live analyst consensus for VKTX.
Options
Sovereign unlock shows live options positioning for VKTX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.